Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
Theresa Klümper(University Hospital Schleswig-Holstein), Ingolf Cascorbi(University Hospital Schleswig-Holstein)
Cited by 36
Related Papers
Metabolic gene polymorphism frequencies in control populations.
|PubMed|2001|847
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper
|Oncology Research and Treatment|2020|88